Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk

Clinical and Experimental Immunology

Volumn 146, Issue 3, 2006, Pages 518-523

  Cabillic, F ^a   Bouet Toussaint, F ^a   Toutirais, O ^a   Rioux Leclercq, N ^a   Fergelot, P ^b   De La Pintière, C Thomas ^c   Genetet, N ^a   Patard, J J ^c   Catros Quemener, V ^a  

^a Inst de Medecine Legale de Rennes   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Cytokine; Dendritic cell; Heat shock protein; Lymphocyte; Renal cell carcinoma

Indexed keywords

CYTOKINE; HEAT SHOCK PROTEIN 70; HYDROGEN PEROXIDE; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN; VASCULOTROPIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL ASSAY; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; HEAT SHOCK; HUMAN; HUMAN CELL; HUMAN TISSUE; IRRADIATION; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ADULT; AGED; CARCINOMA, RENAL CELL; CELL COMMUNICATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HEAT; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HYDROGEN PEROXIDE; INTERLEUKIN-6; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; NECROSIS; NEOPLASM PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33750866727     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03212.x     Document Type: Article

References (34)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15.
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306.
3. Girardi M. Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol 2006; 126:25-31.
4. Seino K, Fujii S, Harada M et al. Valpha14 NKT cell-mediated anti-tumor responses and their clinical application. Springer Semin Immunopathol 2005; 27:65-74.
5. Yee C, Thompson JA, Byrd D et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence,migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99:16168-73.
6. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-57.
7. Friedl P, den Boer AT, Gunzer M. Tuning immune responses: diversity and adaptation of the immunological synapse. Nat Rev Immunol 2005; 5:532-45.
8. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003; 425:397-402.
9. Agnello D, Lankford CS, Bream J et al. Cytokines and transcription factors that regulate T helper cell differentiation. new players and new insights. J Clin Immunol 2003; 23:147-61.
10. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 2005; 6:593-9.
11. Albert ML. Death-defying immunity. do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 2004; 4:223-31.
12. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001; 61:8105-9.
13. Gervais A, Bouet-Toussaint F, Toutirais O, De La Pintiere CT, Genetet N, Catros-Quemener V. Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells. Anticancer Res 2005; 25:2177-85.
14. Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 2004; 111:653-61.
15. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004; 93:297-302.
16. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096-103.
17. Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92:4778-91.
18. Toutirais O, Chartier P, Dubois D et al. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 2003; 14:246-55.
19. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2:46-53.
20. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002; 3:999-1005.
21. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-63.
22. Bouet-Toussaint F, Patard JJ, Gervais A et al. Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use. Cancer Immunol Immunother 2003; 52:699-707.
23. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002; 51:293-8.
24. Gervais A, Leveque J, Bouet-Toussaint F et al. Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res 2005; 7:R326-35.
25. Dikov MM, Ohm JE, Ray N et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005; 174:215-22.
26. Knoefel B, Nuske K, Steiner T et al. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 1997; 17:95-102.
27. Mitropoulos D, Kiroudi A, Christelli E et al. Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res 2004; 32:317-22.
28. Ramp U, Caliskan E, Mahotka C et al. Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. Br J Cancer 2003; 88:1800-7.
29. Chorna I, Bilyy R, Datsyuk L, Stoika R. Comparative study of human breast carcinoma MCF-7 cells differing in their resistance to doxorubicin. effect of ionizing radiation on apoptosis and TGF-beta production. Exp Oncol 2004; 26:111-7.
30. Saito Y, Nishio K, Ogawa Y et al. Turning point in apoptosis/necrosis induced by hydrogen peroxide. Free Radic Res 2006; 40:619-30.
31. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12:1539-46.
32. Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003; 101:4485-91.
33. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2003; 101:245-52.
34. Masse D, Ebstein F, Bougras G, Harb J, Meflah K, Gregoire M. Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy. Int J Cancer 2004; 111:575-83.